Grifols succesfully closes the issuance of additional EUR 300 million secured notes

Barcelona (Spain), June 4, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced the increase by EUR 300 million of its private offering of EUR 1 billion of senior secured notes, closed on April 30, 2024, with the same economic terms: 7.5% annual coupon, due May 2030, and a purchase price of 98.50% of the principal amount of the notes. These notes benefit from the same guarantees and security interest.

Including this increase, Grifols' total issuance has reached EUR 1,300 million.

The proceeds have been received today and will be used to repay part of the revolving loans.

The EUR 1 billion previously issued and paid were used to redeem the Senior Unsecured Notes due May 2025.

This EUR 300 million increase and the successful closing of the previous EUR 1,000 million bond issue, both under the same conditions, demonstrate the confidence of the financial markets in Grifols' solid business and allow the company to strengthen its long- term financial framework.

Grifols has appointed Osborne Clarke and Proskauer Rose LLP as legal advisors. Bank of America and BNP Paribas have acted as placement agents to the Company.

The notes were sold in a private placement to qualified institutional buyers in reliance on section 4(a)(2) of the US Securities Act of 1933, as amended and to non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act.